Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • richrd_cc richrd_cc Aug 20, 2014 10:07 AM Flag

    Ganetespib Study Timeline - may not be complete

    An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant) Estimated Completion Date Dec-14
    Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
    Estimated Completion Date Feb-15
    Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
    Estimated Completion Date A pr-15
    A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
    Estimated Completion Date Sep-15
    Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
    Estimated Completion Date Nov-15
    Ganetespib With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma (MESO-02)
    Estimated Completion Date Dec-15
    A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2) Estimated Completion Date Mar-16
    Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Estimated Completion Date Sep-16
    Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Estimated Completion Date Sep-16
    (continued)

    Sentiment: Strong Buy

 
SNTA
2.12+0.02(+0.95%)Jul 31 4:00 PMEDT